Xiaolong Qi
Impact in
- Hepatology top 0.5%
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 1%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
- Hepatology 105
- Liver Disease and Transplantation 87
- Hepatocellular Carcinoma Treatment and Prognosis 25
- Epidemiology 91
- Liver Disease Diagnosis and Treatment 82
- Co-authors
- Nan Wu (3 shared papers)Guillaume Favre (2 shared papers)David Baud (2 shared papers)Didier Musso (2 shared papers)Karin Nielsen‐Saines (2 shared papers)Léo Pomar (2 shared papers)Dahong Zhang (2 shared papers)Wang Ma (3 shared papers)
- Journals
- Hepatology International (18 papers)Journal of Hepatology (13 papers)Oncotarget (11 papers)Annals of Translational Medicine (6 papers)Gut (6 papers)
- Partner nations
- ChinaUnited StatesIndia
In The Last Decade
Xiaolong Qi
268 papers receiving 9.0k citations
Xiaolong Qi's Hit Papers
Peers
Comparison fields: 5 of 183
- Hepatology 1.8k
- Cancer Research 1.6k
- Infectious Diseases 1.2k
- Modeling and Simulation 267
- Epidemiology 1.5k
Countries citing papers authored by Xiaolong Qi
This map shows the geographic impact of Xiaolong Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaolong Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaolong Qi more than expected).
Fields of papers citing papers by Xiaolong Qi
This network shows the impact of papers produced by Xiaolong Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaolong Qi. The network helps show where Xiaolong Qi may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaolong Qi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 286 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | ceRNA in cancer: possible functions and clinical implications Hit paper breakdown → | 2015 | 1029 |
| 2 | Real estimates of mortality following COVID-19 infection Hit paper breakdown → | 2020 | 889 |
| 3 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update Hit paper breakdown → | 2019 | 645 |
| 4 | ImmunoScore Signature Hit paper breakdown → | 2016 | 360 |
| 5 | 2017 | 237 | |
| 6 | 2020 | 211 | |
| 7 | 2020 | 202 | |
| 8 | 2020 | 184 | |
| 9 | 2020 | 176 | |
| 10 | 2019 | 153 | |
| 11 | 2020 | 147 | |
| 12 | 2017 | 117 | |
| 13 | 2018 | 113 | |
| 14 | Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study Hit paper breakdown → | 2024 | 103 |
| 15 | 2018 | 100 | |
| 16 | 2022 | 91 | |
| 17 | 2020 | 89 | |
| 18 | 2021 | 89 | |
| 19 | 2020 | 88 | |
| 20 | 2017 | 87 |
About Xiaolong Qi
Xiaolong Qi is a scholar working on Hepatology, Epidemiology, Surgery, Oncology and Cancer Research, having authored 286 papers that have together received 9.1k indexed citations. Recurring topics across this work include Liver Disease and Transplantation (87 papers), Liver Disease Diagnosis and Treatment (82 papers), Hepatocellular Carcinoma Treatment and Prognosis (25 papers), Organ Transplantation Techniques and Outcomes (13 papers), COVID-19 Clinical Research Studies (10 papers), MicroRNA in disease regulation (9 papers), Circular RNAs in diseases (9 papers) and Cancer-related molecular mechanisms research (8 papers). The work is most often cited by research in Hepatology (1.8k citations), Cancer Research (1.6k citations), Infectious Diseases (1.2k citations), Modeling and Simulation (267 citations) and Epidemiology (1.5k citations). Xiaolong Qi has collaborated with scholars based in China, United States and India. Frequent co-authors include Nan Wu, Guillaume Favre, David Baud, Didier Musso, Karin Nielsen‐Saines, Léo Pomar, Dahong Zhang, Wang Ma, Xiang Wang and Junhua Xiao. Their work appears in journals such as Hepatology International, Journal of Hepatology, Oncotarget, Annals of Translational Medicine and Gut.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.